Michael P. Endsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael P. Endsley has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
William B. Campbell
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI
5 shared publications- Kasem Nithipatikom
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
4 shared publications Marilyn A. Isbell
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI
4 shared publicationsBruce D. Hammock
Department of Entomology and Cancer Research Center, University of California, Davis, CA
2 shared publicationsCraig E. Wheelock
Department of Entomology and Cancer Research Center, University of California, Davis, CA
2 shared publicationsJohn R. Falck
Departments of Biochemistry and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390
2 shared publications
Latest Publications
- Open Access
- 1 October 2014
- Published by Elsevier in Journal of Lipid Research
- Vol. 55 (10) , 2093-2102
A novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol
- 1 October 2014
- Published by Elsevier in Journal of Lipid Research
- Vol. 55 (10) , 2093-2102
Open AccessA novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol
- Open Access
- 1 July 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (28) , 24599-24607
Maspin, the Molecular Bridge between the Plasminogen Activator System and β1 Integrin That Facilitates Cell Adhesion
- 1 July 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (28) , 24599-24607
Open AccessMaspin, the Molecular Bridge between the Plasminogen Activator System and β1 Integrin That Facilitates Cell Adhesion
- 1 January 2011
- Published by Elsevier
- Vol. 499, 149-165
Investigating Maspin in Breast Cancer Progression Using Mouse Models
- 1 January 2011
- Published by Elsevier
- Vol. 499, 149-165
Investigating Maspin in Breast Cancer Progression Using Mouse Models
- Open Access
- 19 June 2008
- Published by Wiley in International Journal of Cancer
- Vol. 123 (6) , 1318-1326
Expression and function of fatty acid amide hydrolase in prostate cancer
The hydrolysis of endocannabinoids has profound effects on the function of the endocannabinoid signaling system in the regulation of prostate carcinoma cells. Prostate carcinoma cells exhibit a wide range of hydrolysis activity for 2‐arachidonoylglycerol (2‐AG), the major endocannabinoid. However, enzyme(s) responsible for 2‐AG hydrolysis and their functions in prostate cancer have not been characterized. In this study, we demonstrated that fatty acid amide hydrolase (FAAH) was differentially expressed in normal and prostate carcinoma cells. In PC‐3 cells, overexpression of FAAH resulted in increased FAAH protein, 2‐AG hydrolysis, cell invasion and cell migration. Conversely, small‐interfering RNA (siRNA) knockdown of FAAH in LNCaP cells decreased FAAH protein, 2‐AG hydrolysis and cell invasion. Furthermore, CAY10401, a FAAH inhibitor, decreased cell invasion and it enhanced the reduction of invasion in FAAH siRNA‐transfected LNCaP cells. Immunohistochemistry staining of commercial tissue microarrays (TMAs) demonstrated FAAH staining in 109 of 157 cores of prostate adenocarcinomas but weak staining in 1 of 8 cores of normal prostate tissues. These results suggest that FAAH regulates 2‐AG hydrolysis and invasion of prostate carcinoma cells and is potentially involved in prostate tumorigenesis.
- 19 June 2008
- Published by Wiley in International Journal of Cancer
- Vol. 123 (6) , 1318-1326
Open AccessExpression and function of fatty acid amide hydrolase in prostate cancer
The hydrolysis of endocannabinoids has profound effects on the function of the endocannabinoid signaling system in the regulation of prostate carcinoma cells. Prostate carcinoma cells exhibit a wide range of hydrolysis activity for 2‐arachidonoylglycerol (2‐AG), the major endocannabinoid. However, enzyme(s) responsible for 2‐AG hydrolysis and their functions in prostate cancer have not been characterized. In this study, we demonstrated that fatty acid amide hydrolase (FAAH) was differentially expressed in normal and prostate carcinoma cells. In PC‐3 cells, overexpression of FAAH resulted in increased FAAH protein, 2‐AG hydrolysis, cell invasion and cell migration. Conversely, small‐interfering RNA (siRNA) knockdown of FAAH in LNCaP cells decreased FAAH protein, 2‐AG hydrolysis and cell invasion. Furthermore, CAY10401, a FAAH inhibitor, decreased cell invasion and it enhanced the reduction of invasion in FAAH siRNA‐transfected LNCaP cells. Immunohistochemistry staining of commercial tissue microarrays (TMAs) demonstrated FAAH staining in 109 of 157 cores of prostate adenocarcinomas but weak staining in 1 of 8 cores of normal prostate tissues. These results suggest that FAAH regulates 2‐AG hydrolysis and invasion of prostate carcinoma cells and is potentially involved in prostate tumorigenesis.
- Open Access
- 18 April 2007
- Published by Wiley in International Journal of Cancer
- Vol. 121 (5) , 984-991
Diverse roles of 2‐arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12‐lipoxygenase metabolism
Endogenous 2‐arachidonoylglycerol (2‐AG) is antiinvasive in androgen‐independent prostate carcinoma (PC‐3) cells. Invasion of PC‐3 cells is also inhibited by exogenously added noladin ether, a non‐hydrolyzable analog of 2‐AG. In contrast, exogenous 2‐AG has the opposite effect. Cell invasion significantly increased with high concentrations of exogenous 2‐AG. In PC‐3 cells, arachidonic acid (AA) and 12‐hydroxyeicosatetraenoic acid (12‐HETE) concentrations increased along with exogenously added 2‐AG, and 12‐HETE concentrations increased with exogenously added AA. Invasion of PC‐3 cells also increased with exogenously added AA and 12(S)‐HETE but not 12(R)‐HETE. The exogenous 2‐AG‐induced invasion of PC‐3 cells was inhibited by 3‐octylthio‐1,1,1‐trifluoropropan‐2‐one (OTFP, an inhibitor of 2‐AG hydrolysis) and baicalein (a 12‐LO inhibitor). Western blot and RT‐PCR analyses indicated expression of 12‐HETE producing lipoxygenases (LOs), platelet‐type 12‐LO (P‐12‐LO) and leukocyte‐type 12‐LO (L‐12‐LO), in PC‐3 cells. These results suggest that exogenous 2‐AG induced, rather inhibited, cell invasion because of its rapid hydrolysis to free AA, and further metabolism by 12‐LO of AA to 12(S)‐HETE, a promoter of PC cell invasion. The results also suggest that PC‐3 cells and human prostate stromal (WPMY‐1) cells released free AA, 2‐AG, and 12‐HETE. In the microenvironment of the PC cells, this may contribute to the cell invasion. The 2‐AG hydrolysis and concentration of 2‐AG in microenvironment are critical for PC cell's fate. Therefore, inhibitors of 2‐AG hydrolysis could potentially serve as therapeutic agents for the treatment of prostate cancer.
- 18 April 2007
- Published by Wiley in International Journal of Cancer
- Vol. 121 (5) , 984-991
Open AccessDiverse roles of 2‐arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12‐lipoxygenase metabolism
Endogenous 2‐arachidonoylglycerol (2‐AG) is antiinvasive in androgen‐independent prostate carcinoma (PC‐3) cells. Invasion of PC‐3 cells is also inhibited by exogenously added noladin ether, a non‐hydrolyzable analog of 2‐AG. In contrast, exogenous 2‐AG has the opposite effect. Cell invasion significantly increased with high concentrations of exogenous 2‐AG. In PC‐3 cells, arachidonic acid (AA) and 12‐hydroxyeicosatetraenoic acid (12‐HETE) concentrations increased along with exogenously added 2‐AG, and 12‐HETE concentrations increased with exogenously added AA. Invasion of PC‐3 cells also increased with exogenously added AA and 12(S)‐HETE but not 12(R)‐HETE. The exogenous 2‐AG‐induced invasion of PC‐3 cells was inhibited by 3‐octylthio‐1,1,1‐trifluoropropan‐2‐one (OTFP, an inhibitor of 2‐AG hydrolysis) and baicalein (a 12‐LO inhibitor). Western blot and RT‐PCR analyses indicated expression of 12‐HETE producing lipoxygenases (LOs), platelet‐type 12‐LO (P‐12‐LO) and leukocyte‐type 12‐LO (L‐12‐LO), in PC‐3 cells. These results suggest that exogenous 2‐AG induced, rather inhibited, cell invasion because of its rapid hydrolysis to free AA, and further metabolism by 12‐LO of AA to 12(S)‐HETE, a promoter of PC cell invasion. The results also suggest that PC‐3 cells and human prostate stromal (WPMY‐1) cells released free AA, 2‐AG, and 12‐HETE. In the microenvironment of the PC cells, this may contribute to the cell invasion. The 2‐AG hydrolysis and concentration of 2‐AG in microenvironment are critical for PC cell's fate. Therefore, inhibitors of 2‐AG hydrolysis could potentially serve as therapeutic agents for the treatment of prostate cancer.
- 1 July 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 332 (4) , 1028-1033
A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells
- 1 July 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 332 (4) , 1028-1033
A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells
- 15 December 2004
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (24) , 8826-8830
2-Arachidonoylglycerol
Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.
- 15 December 2004
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (24) , 8826-8830
2-Arachidonoylglycerol
Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.
- 15 October 2004
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 95 (8) , e65-71
Inhibition of Cytochrome P450ω-Hydroxylase
Cytochrome P450s (CYP) and their arachidonic acid (AA) metabolites have important roles in regulating vascular tone, but their function and specific pathways involved in modulating myocardial ischemia–reperfusion injury have not been clearly established. Thus, we characterized the effects of several selective CYPω-hydroxylase inhibitors and a CYPω-hydroxylase metabolite of AA, 20-hydroxyeicosatetraenoic acid (20-HETE), on the extent of ischemia–reperfusion injury in canine hearts. During 60 minutes of ischemia and particularly after 3 hours of reperfusion, 20-HETE was produced at high concentrations. A nonspecific CYP inhibitor, miconazole, and 2 specific CYPω-hydroxylase inhibitors, 17-octadecanoic acid (17-ODYA) and N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), markedly inhibited 20-HETE production during ischemia–reperfusion and produced a profound reduction in myocardial infarct size (expressed as a percent of the area at risk) (19.6±1.7% [control], 8.4±2.5% [0.96 mg/kg miconazole], 5.9±2.2% [0.28 mg/kg 17-ODYA], and 10.8±1.8% [0.40 mg/kg DDMS], P P <0.05). Several CYPω-hydroxylase isoforms, which are known to produce 20-HETE such as CYP4A1, CYP4A2, and CYP4F, were demonstrated to be present in canine heart tissue and their activity was markedly inhibited by incubation with 17-ODYA. These results indicate an important endogenous role for CYPω-hydroxylases and in particular their product, 20-HETE, in exacerbating myocardial injury in canine myocardium. The full text of this article is available online at http://circres.ahajournals.org.
- 15 October 2004
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 95 (8) , e65-71
Inhibition of Cytochrome P450ω-Hydroxylase
Cytochrome P450s (CYP) and their arachidonic acid (AA) metabolites have important roles in regulating vascular tone, but their function and specific pathways involved in modulating myocardial ischemia–reperfusion injury have not been clearly established. Thus, we characterized the effects of several selective CYPω-hydroxylase inhibitors and a CYPω-hydroxylase metabolite of AA, 20-hydroxyeicosatetraenoic acid (20-HETE), on the extent of ischemia–reperfusion injury in canine hearts. During 60 minutes of ischemia and particularly after 3 hours of reperfusion, 20-HETE was produced at high concentrations. A nonspecific CYP inhibitor, miconazole, and 2 specific CYPω-hydroxylase inhibitors, 17-octadecanoic acid (17-ODYA) and N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), markedly inhibited 20-HETE production during ischemia–reperfusion and produced a profound reduction in myocardial infarct size (expressed as a percent of the area at risk) (19.6±1.7% [control], 8.4±2.5% [0.96 mg/kg miconazole], 5.9±2.2% [0.28 mg/kg 17-ODYA], and 10.8±1.8% [0.40 mg/kg DDMS], P P <0.05). Several CYPω-hydroxylase isoforms, which are known to produce 20-HETE such as CYP4A1, CYP4A2, and CYP4F, were demonstrated to be present in canine heart tissue and their activity was markedly inhibited by incubation with 17-ODYA. These results indicate an important endogenous role for CYPω-hydroxylases and in particular their product, 20-HETE, in exacerbating myocardial injury in canine myocardium. The full text of this article is available online at http://circres.ahajournals.org.